New drug cocktail aims to tame rare immune disease

NCT ID NCT07187167

First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 23 times

Summary

This study tests whether a combination of lenalidomide and dexamethasone can control Rosai-Dorfman disease, a rare disorder where immune cells build up and cause lumps. About 40 adults aged 18 to 80 who are newly diagnosed or have not responded to prior treatment will receive the drug regimen. The main goal is to see how long the disease stays under control without worsening.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ROSAI DORFMAN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.